Drug Trial Radar · NCT00175903
Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy
Last checked: Nov 19, 2026Latest source record: Mar 17, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,701
Actual
Start
Feb 2005
Primary completion
Oct 2007
Study completion Oct 2007
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study N01175 was to compare overall effectiveness (efficacy and safety) of levetiracetam (LEV) versus the 2 older antiepileptic drugs (AEDs), sodium valproate extended release (VPA-ER) and carbamazepine controlled release (CBZ-CR) in the treatment of subjects with newly diagnosed epilepsy.
Conditions
- Epilepsy
Interventions
LevetiracetamDrug
Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
Carbamazepine Controlled Release (CBZ-CR)Drug
Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
Valproate Extended ReleaseDrug
Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to withdrawal from study medication (starting at V1) as a measure of combined efficacy and safetyTime frame: Visit 1 to End of Study (approximately 52 weeks)
Locations
229 sites in 24 countries. Site status is shown where the registry gives one.
Site not named
Adelaide, Australia
Site not named
Bedford Park, Australia
Site not named
Brisbane, Australia
Site not named
Cairns, Australia
Site not named
Camperdown, Australia
Site not named
Chatswood, Australia
Site not named
Clayton, Australia
Site not named
Maroochydore, Australia
Site not named
Parkville, Australia
Site not named
Perth, Australia
Site not named
Randwick, Australia
Site not named
West Heidelberg, Australia
Site not named
Graz, Austria
Site not named
Innsbrick, Austria
Site not named
Klagenfurt, Austria
Site not named
Linz, Austria
Site not named
Steyr, Austria
Site not named
Vienna, Austria
Site not named
Bruges, Belgium
Site not named
Dendermonde, Belgium
Site not named
Edegem, Belgium
Site not named
Ghent, Belgium
Site not named
Haine-Saint-Paul, Belgium
Site not named
Jette, Belgium
Site not named
Kortrijk, Belgium
Site not named
Leuven, Belgium
Site not named
Ostend, Belgium
Site not named
Ottignies, Belgium
Site not named
Plovdiv, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Varna, Bulgaria
Site not named
Litomyšl, Czechia
Site not named
Ostrava-Poruba, Czechia
Site not named
Zlín, Czechia
Site not named
Aalborg, Denmark
Site not named
Copenhagen, Denmark
Site not named
Holbæk, Denmark
Site not named
Holstebro, Denmark
Site not named
Hus (Helsinki), Finland
Site not named
Kuopio, Finland
Showing 40 of 229 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.